NCT05626634 2025-12-03
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 2 Completed
Clinical Trials
10 trialsNCT04485104 2025-10-31
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals
Phase 3 Terminated
NCT04106219 2025-07-23
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03731455 2025-07-17
WIN
Wise S.r.l.
Phase NA Completed
NCT05364021 2024-11-08
PACIFIC
Longboard Pharmaceuticals
Phase 1/2 Completed
NCT02134067 2024-09-05
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Terminated
NCT04737174 2022-04-06
ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
ES Therapeutics Australia Pty Ltd
Phase 2 Withdrawn
NCT03898791 2021-08-05
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT03955939 2020-06-01
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
Eli Lilly and Company
Phase 1 Completed